Cognition Therapeutics Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
DATE: | July 29, 2024 |
---|---|
TIME: | 8:30 AM EDT |
LOCATION: | Virtual |
About The Event
Join Cognition Therapeutics for an investor webcast to discuss the clinical efficacy, safety and biomarker findings from the Phase 2 COG0201 “SHINE” study, which will be presented at the upcoming Alzheimer’s Association’s International Conference being held from July 28 – August 1, 2024.
The event will feature an investigator in the SHINE study, Everard (Jort) Vijverberg, MD, PhD of the Alzheimer Center Amsterdam and Neuroscience Amsterdam, who will present an overview of the Phase 2 COG0201 “SHINE” study results, and Martin J. Sadowski, MD, PhD, DSci of New York University School of Medicine, who will participate as an Alzheimer’s industry expert.
A live question and answer session will follow formal presentations.